Vivian Ruvolo

List of Publications by Year
in descending order

46 papers	1,247 citations	471371 17 h-index	377752 34 g-index
47 all docs	47 docs citations	47 times ranked	2082 citing authors

#	Article	IF	Citations
1	Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica, 2022, 107, 58-76.	1.7	62
2	Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Translational Oncology, 2022, 18, 101354.	1.7	9
3	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia, 2022, 36, 1261-1273.	3.3	12
4	Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition. Blood Advances, 2021, 5, 4233-4255.	2.5	36
5	Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. Blood, 2021, 138, 505-505.	0.6	1
6	Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2020, 19, 1636-1648.	1.9	13
7	Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. Blood, 2020, 136, 19-20.	0.6	18
8	Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-Î²-p38-ALDH2 pathway. PLoS ONE, 2020, 15, e0242809.	1.1	19
9	BCL2A1: A Novel Target in Refractory Acute Myeloid Leukemia with FLT3-ITD/D835 Dual Mutations. Blood, 2020, 136, 32-33.	0.6	0
10	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. Blood, 2020, 136, 18-20.	0.6	2
11	High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML. Blood, 2020, 136, 15-15.	0.6	3
12	Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML. Blood, 2020, 136, 30-31.	0.6	1
13	The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia. Blood, 2020, 136, 8-9.	0.6	0
14	The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML. Blood, 2020, 136, 11-11.	0.6	0
15	Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias. Blood, 2020, 136, 23-24.	0.6	1
16	Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML. Blood, 2020, 136, 7-7.	0.6	3
17	Title is missing!. , 2020, 15, e0242809.		0
18	Title is missing!. , 2020, 15, e0242809.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0242809.		0
20	Title is missing!. , 2020, 15, e0242809.		0
21	An ARC-Regulated IL1Î²/Cox-2/PGE2/Î²-Catenin/ARC Circuit Controls Leukemiaâ€“Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Research, 2019, 79, 1165-1177.	0.4	38
22	Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia, 2019, 33, 2805-2816.	3.3	47
23	BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment. Journal of Clinical Investigation, 2019, 129, 1878-1894.	3.9	51
24	TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia. Blood, 2019, 134, 1251-1251.	0.6	1
25	Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns. Blood, 2019, 134, 882-882.	0.6	1
26	Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML. Blood, 2019, 134, 911-911.	0.6	11
27	Oxidized analogs of Di(1H-indol-3-yl)methyl-4-substituted benzenes are NR4A1-dependent UPR inducers with potent and safe anti-cancer activity. Oncotarget, 2018, 9, 25057-25074.	0.8	5
28	Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Scientific Reports, 2018, 8, 16837.	1.6	36
29	Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica, 2018, 103, 1642-1653.	1.7	33
30	Mitochondrial Transfer Confers Microenvironment-Mediated Resistance to Oxphos Inhibition in AML. Blood, 2018, 132, 430-430.	0.6	0
31	Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL. Blood, 2018, 132, 890-890.	0.6	0
32	Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. Cancer Research, 2017, 77, 1453-1464.	0.4	123
33	Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell, 2017, 32, 748-760.e6.	7.7	206
34	AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight, 2017, 2, .	2.3	98
35	Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget, 2017, 8, 83354-83369.	0.8	7
36	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood, 2016, 128, 1260-1269.	0.6	104

#	Article	IF	Citations
37	ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling, 2016, 9, ra17.	1.6	147
38	Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFÎºB/IL1Î² signaling network. Oncotarget, 2016, 7, 20054-20067.	0.8	32
39	Novel Fatty Acid Oxidation Inhibitor Avocatinb Induces AMPK-Dependent Apoptosis of AML Cells Co-Cultured with BM-Adipocytes. Blood, 2016, 128, 3947-3947.	0.6	0
40	Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. PLoS ONE, 2015, 10, e0138377.	1.1	21
41	MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. PLoS ONE, 2015, 10, e0139254.	1.1	23
42	BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms. Blood, 2015, 126, 673-673.	0.6	4
43	Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood, 2013, 122, 357-366.	0.6	77
44	Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML. Blood, 2012, 120, 534-534.	0.6	0
45	The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia. Blood, 2011, 118, 2480-2480.	0.6	0
46	MDM2 Inhibitor Nutlin-3a Triggers Autophagic Cell Death In Addition to Apoptosis In Leukemia Cell Lines with Wild-Type p53. Blood, 2010, 116, 3300-3300.	0.6	1